US-based biopharmaceutical company Accent Therapeutics has dosed the first subject in an open-label Phase I/II trial of ...

First-in-human Phase 1/2 study initiated for ATX-295, a potential best-in-class oral inhibitor of KIF18A, focused on patients with advanced solid tumors including ovarian cancer FDA grants Fast ...